We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
DaVita (DVA) Q4 Earnings and Revenues Fall Shy of Estimates
Read MoreHide Full Article
DaVita Inc. (DVA - Free Report) reported fourth-quarter 2020 adjusted earnings per share (EPS) of $1.67, missing the Zacks Consensus Estimate of $1.85 by 9.7%. The bottom line also fell 10.2% from the year-ago quarter’s figure.
For 2020, adjusted EPS came in at $7.26, missing the Zacks Consensus Estimate of $7.43 by 2.3%.The bottomline, however, rose 34.4% year over year.
Revenues
Total revenues in the quarter rose 0.7% year over year to $2.91 billion but missed the Zacks Consensus Estimate by 1%.
For 2020, revenues came in at $11.55 billion, also missing the Zacks Consensus Estimate by 0.3%.The topline, however, rose 1.4% year over year.
Segment Details
Net dialysis and related lab patient service revenues in the fourth quarter totaled $2.77 billion, up 0.3% on a year-over-year basis. Other revenues were $132.2 million, down 0.3% from the year-ago quarter’s figure.
Per management, total U.S. dialysis treatments for the fourth quarter were 7,574,217 or 95,876 treatments, on average per day. This represents a per-day decrease of 0.9% on a year-over-year basis.
Also, as of Dec 31, 2020, the company provided dialysis services to a total of approximately 240,400 patients at 3,137 outpatient dialysis centers, of which 2,816 centers were located in the United States and 321 in 10 other countries.
During the quarter, DaVita opened a total of 14 dialysis centers and closed seven in the United States. The company also acquired 30 dialysis centers outside the United States including foraying into a new country, which is the United Kingdom, during the fourth quarter of 2020.
Margin
Total operating expenses and charges amounted to $2.52 billion, up 3.3% year over year.
Adjusted operating income of $382 million fell 17.4% from the prior-year quarter. Adjusted operating margin came in at 13.1%, down 290 basis points (bps) from the year-ago quarter.
DaVita exited the fourth quarter of 2020 with cash and cash equivalents of $324.9 million compared with $1.10 billion at the end of the year-ago period.
Cumulative net cash from operating activities of $1.97 billion compared unfavorably with $2.07 billion in the year-ago quarter.
2021 Guidance
Adjusted EPS is projected within $7.75 -$8.75, up from the previous guidance of $7.35-$7.60. The Zacks Consensus Estimate for the same stands at $8.14.
Adjusted operating income is anticipated between $1.68 billion and $1.83 billion.
Our Take
DaVita ended the fourth quarter on a weak note. Nonetheless, net dialysis and related lab patient service revenues increased during the quarter. The acquisition of several dialysis centers overseas is encouraging as well. A solid guidance for 2021 is another positive.
Notably, the company repurchased shares worth $417 million in the quarter under review.
However, foreign exchange headwinds and stiff competition continue to weigh on the company. Contraction of adjusted operating margin is another concern.
Zacks Rank and Key Picks
DaVita currently carries a Zacks Rank #5 (Strong Sell).
Some better-ranked stocks in the broader medical space that already announced quarterly results are Hologic, Inc. (HOLX - Free Report) , Abbott Laboratories (ABT - Free Report) and AngioDynamics, Inc. (ANGO - Free Report) . While Hologic sports a Zacks Rank #1 (Strong Buy), the other two presently carry a Zacks Rank#2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Hologic reported first-quarter fiscal 2021 adjusted EPS of $2.86, which surpassed the Zacks Consensus Estimate by 33.6%.
Abbott reported fourth-quarter 2020 adjusted EPS of $1.45, which surpassed the Zacks Consensus Estimate by 6.6%. Further, fourth-quarter worldwide sales of $10.7 billion outpaced the consensus mark by 7.9%.
AngioDynamics reported second-quarter fiscal 2021 adjusted EPS of a penny. The Zacks Consensus Estimate was of a loss per share of a couple ofcents. Additionally, revenues of $72.8 million beat the consensus mark by 8%.
Zacks Top 10 Stocks for 2021
In addition to the stocks discussed above, would you like to know about our 10 best buy-and-hold tickers for the entirety of 2021?
Last year's 2020Zacks Top 10 Stocks portfolio returned gains as high as +386.8%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys.
Image: Bigstock
DaVita (DVA) Q4 Earnings and Revenues Fall Shy of Estimates
DaVita Inc. (DVA - Free Report) reported fourth-quarter 2020 adjusted earnings per share (EPS) of $1.67, missing the Zacks Consensus Estimate of $1.85 by 9.7%. The bottom line also fell 10.2% from the year-ago quarter’s figure.
For 2020, adjusted EPS came in at $7.26, missing the Zacks Consensus Estimate of $7.43 by 2.3%.The bottomline, however, rose 34.4% year over year.
Revenues
Total revenues in the quarter rose 0.7% year over year to $2.91 billion but missed the Zacks Consensus Estimate by 1%.
For 2020, revenues came in at $11.55 billion, also missing the Zacks Consensus Estimate by 0.3%.The topline, however, rose 1.4% year over year.
Segment Details
Net dialysis and related lab patient service revenues in the fourth quarter totaled $2.77 billion, up 0.3% on a year-over-year basis. Other revenues were $132.2 million, down 0.3% from the year-ago quarter’s figure.
Per management, total U.S. dialysis treatments for the fourth quarter were 7,574,217 or 95,876 treatments, on average per day. This represents a per-day decrease of 0.9% on a year-over-year basis.
Also, as of Dec 31, 2020, the company provided dialysis services to a total of approximately 240,400 patients at 3,137 outpatient dialysis centers, of which 2,816 centers were located in the United States and 321 in 10 other countries.
During the quarter, DaVita opened a total of 14 dialysis centers and closed seven in the United States. The company also acquired 30 dialysis centers outside the United States including foraying into a new country, which is the United Kingdom, during the fourth quarter of 2020.
Margin
Total operating expenses and charges amounted to $2.52 billion, up 3.3% year over year.
Adjusted operating income of $382 million fell 17.4% from the prior-year quarter. Adjusted operating margin came in at 13.1%, down 290 basis points (bps) from the year-ago quarter.
DaVita Inc. Price, Consensus and EPS Surprise
DaVita Inc. price-consensus-eps-surprise-chart | DaVita Inc. Quote
Financial Condition
DaVita exited the fourth quarter of 2020 with cash and cash equivalents of $324.9 million compared with $1.10 billion at the end of the year-ago period.
Cumulative net cash from operating activities of $1.97 billion compared unfavorably with $2.07 billion in the year-ago quarter.
2021 Guidance
Adjusted EPS is projected within $7.75 -$8.75, up from the previous guidance of $7.35-$7.60. The Zacks Consensus Estimate for the same stands at $8.14.
Adjusted operating income is anticipated between $1.68 billion and $1.83 billion.
Our Take
DaVita ended the fourth quarter on a weak note. Nonetheless, net dialysis and related lab patient service revenues increased during the quarter. The acquisition of several dialysis centers overseas is encouraging as well. A solid guidance for 2021 is another positive.
Notably, the company repurchased shares worth $417 million in the quarter under review.
However, foreign exchange headwinds and stiff competition continue to weigh on the company. Contraction of adjusted operating margin is another concern.
Zacks Rank and Key Picks
DaVita currently carries a Zacks Rank #5 (Strong Sell).
Some better-ranked stocks in the broader medical space that already announced quarterly results are Hologic, Inc. (HOLX - Free Report) , Abbott Laboratories (ABT - Free Report) and AngioDynamics, Inc. (ANGO - Free Report) . While Hologic sports a Zacks Rank #1 (Strong Buy), the other two presently carry a Zacks Rank#2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Hologic reported first-quarter fiscal 2021 adjusted EPS of $2.86, which surpassed the Zacks Consensus Estimate by 33.6%.
Abbott reported fourth-quarter 2020 adjusted EPS of $1.45, which surpassed the Zacks Consensus Estimate by 6.6%. Further, fourth-quarter worldwide sales of $10.7 billion outpaced the consensus mark by 7.9%.
AngioDynamics reported second-quarter fiscal 2021 adjusted EPS of a penny. The Zacks Consensus Estimate was of a loss per share of a couple ofcents. Additionally, revenues of $72.8 million beat the consensus mark by 8%.
Zacks Top 10 Stocks for 2021
In addition to the stocks discussed above, would you like to know about our 10 best buy-and-hold tickers for the entirety of 2021?
Last year's 2020Zacks Top 10 Stocks portfolio returned gains as high as +386.8%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys.
Access Zacks Top 10 Stocks for 2021 today >>